Related Experiment Video
Updated: Jun 23, 2026
08:27
Real-time Cytotoxicity Assays in Human Whole Blood
Published on: November 7, 2014
[Anti-CD20 therapy in rheumatoid arthritis]
1Schwerpunkt Rheumatologie/Klinische Immunologie, Medizinische Klinik und Poliklinik II, Universität Würzburg, Würzburg. roll_p@medizin.uni-wuerzburg.de
Zeitschrift Fur Rheumatologie
|May 19, 2009
Summary
Rituximab, a B-cell therapy, effectively treats rheumatoid arthritis by halting joint destruction. While infusion reactions are common, they can be managed, and the treatment shows sustained efficacy with good tolerance upon re-treatment.
Area of Science:
- Immunology
- Rheumatology
- Pharmacology
Context:
- Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation and destruction.
- Tumor necrosis factor-inhibitors (TNF-inhibitors) are a common treatment for RA, but some patients exhibit a poor response.
- B-cell depletion therapy offers an alternative treatment strategy for RA.
Purpose:
- To evaluate the efficacy and safety of Rituximab, an anti-CD20 antibody, in patients with rheumatoid arthritis who have a poor response to TNF-inhibitors.
- To assess the impact of Rituximab on clinical parameters and radiological progression of joint destruction.
- To analyze the tolerability and side effect profile of Rituximab treatment, including infusion reactions and serious infections.
Summary:
- The REFLEX study demonstrated that Rituximab, administered with Methotrexate, significantly improved clinical parameters in RA patients unresponsive to TNF-inhibitors.
- Radiological evidence confirmed Rituximab's ability to arrest joint destruction effectively.
- The treatment was generally well-tolerated, with manageable infusion reactions (reduced by steroid premedication) and a slightly increased rate of serious infections compared to placebo.
Impact:
- Rituximab established itself as the first B-cell-specific therapy for rheumatoid arthritis, offering a new therapeutic option for patients with inadequate response to existing treatments.
- The study provided robust evidence for the disease-modifying effects of Rituximab, including the prevention of joint damage.
- Long-term data indicate sustained efficacy and good tolerability with repeated Rituximab administration, supporting its role in the management of rheumatoid arthritis.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Autoimmune Disorders
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...
Concept and Mechanism of Autoimmune Diseases
The immune system...
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:21Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...